Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVALANCHE: Avandamet or Avandia+Amaryl vs Metformin in T2DM
NCT00131664Phase 3Completed
- Sponsor
- Canadian Heart Research Centre
- Start
- Sep 2005
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rosiglitazone in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Canadian Heart Research Centre. Primary endpoint: Mean Change From Baseline in A1C at 6 months. Started Sep 2005; status: completed.
02
Drugs
rosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00131664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131664.